AGP Executive Report
Last update: 9 hours agoRegulatory & Access: The FDA approved Eli Lilly’s once-weekly basal insulin Onswik for adults with type 2 diabetes, extending a growing push toward simpler dosing; the FDA also cleared additional therapies including obinutuzumab for idiopathic nephrotic syndrome and new approvals in oncology and rare disease. Drug Pricing Pressure: Novartis and Eli Lilly opposed an Indian court bid to cut breast cancer drug prices, arguing costs and pointing to limited India sales versus global revenue. Workforce & System Capacity: In the UK, the Royal College of Physicians backed a Health Foundation call for long-term NHS workforce planning and retention to protect patient care. Global Health Security: India urged fair pathogen access and benefit sharing under the WHO Pandemic Agreement, stressing resilient health systems and lab capacity. Pharma Operations: New fill-finish and modular packaging approaches are gaining traction to improve sterility assurance and handle smaller, more personalized batches. Policy & Labor: A settlement paused litigation over unlawful mass federal firings during a prior shutdown, requiring agencies to remove RIF authorization from shutdown plans.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
